Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes

US8022046B2 · kind B2 · utility

Assignees

• Baxter International Inc. · US
• University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

• Larry R. Brown · Newton, US
• Nick Giannoukakis · Pittsburgh, US
• Massimo M. Trucco · Pittsburgh, US

Key dates

• Filing date: Apr 20, 2009
• Grant date: Sep 20, 2011
• Expiry date: Apr 29, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method is provided that includes using an antisense approach to reverse and/or delay an autoimmune diabetes condition in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.